Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Ontology highlight
ABSTRACT: Biliary tract cancers (BTC) comprise a group of rare and heterogeneous poor-prognosis tumours with the incidence of intrahepatic cholangiocarcinoma increasing over recent years. Combination chemotherapy with gemcitabine and cisplatin is the established first-line treatment for advanced BTC with a significant but modest survival advantage over monotherapy. There remains no accepted standard treatment in the second-line setting, although recent results from a randomised study have shown a survival benefit with 5-fluorouracil and oxaliplatin chemotherapy. Historically, clinical trials investigating targeted therapies in unselected BTC have failed to demonstrate significant clinical benefit. More recently, advancement in molecular exploration of BTC has shed light on the complex biological het
SUBMITTER: Athauda A
PROVIDER: S-EPMC8222858 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA